Replimune Group, INC Schedule 13G passive stakes
Filed when an investor crosses five percent without intending to seek control — the passive counterpart to a 13D.
NASDAQ
Goldman Sachs Group, Inc. and its subsidiary Goldman Sachs & Co. LLC have updated their beneficial ownership filing for REPLIMUNE GROUP INC, reporting a 5.3% stake.
NASDAQ
State Street Corporation has reported beneficial ownership of 5.3% of Replimune Group Inc.'s common stock as of June 30, 2026.
NASDAQ
Montanova Capital, LLC, Averill Master Fund, Ltd., and Aaron Cowen have filed an amendment to their Schedule 13G, reporting changes in beneficial ownership of Replimune Group, Inc. common stock.
NASDAQ
Ridgeback Capital Investments has filed a Schedule 13G reporting a 7.6% beneficial ownership stake in Replimune Group, Inc.
NASDAQ
RTW Investments, LP and Roderick Wong report beneficial ownership of 8.9% of Replimune Group, Inc. common stock as of March 31, 2026.
NASDAQ
Suvretta Capital Management, LLC and Aaron Cowen have filed a Schedule 13G reporting a 5.1% beneficial ownership stake in Replimune Group, Inc.
NASDAQ
T. Rowe Price Associates, Inc. has filed a Schedule 13G, reporting beneficial ownership of 0.2% of Replimune Group Inc.'s common stock as of April 30, 2026.
NASDAQ
SCHEDULE: Forbion Reduces Replimune Stake to 3.5%
Forbion Capital Fund III and Forbion III Management B.V. have reduced their beneficial ownership in Replimune Group, Inc. to 3.5% of outstanding common stock.
NASDAQ
Redmile Group, LLC and its principal, Jeremy C. Green, reported a 0.7% beneficial ownership stake in Replimune Group, Inc., holding 535,818 shares as of September 30, 2025.
NASDAQ
Point72 Asset Management, along with Point72 Capital Advisors Inc. and Steven A. Cohen, has reported a beneficial ownership of 4.7% in Replimune Group, Inc. common stock.
NASDAQ
T. Rowe Price Associates, Inc. has reported a 10.6% beneficial ownership stake in Replimune Group Inc. common stock as of September 30, 2025.
NASDAQ
RTW Investments, LP and Roderick Wong, M.D. have jointly filed a Schedule 13G, reporting beneficial ownership of 8.2% of Replimune Group, Inc.'s common stock.
NASDAQ
Point72 Asset Management, along with its affiliates and founder Steven A. Cohen, has disclosed a beneficial ownership of 5.7% in Replimune Group, Inc.
NASDAQ
SCHEDULE 13G/A: Redmile Group Discloses 6.4% Stake in Replimune Group, Inc.
Investment firm Redmile Group, LLC and its principal Jeremy C. Green have disclosed a 6.4% beneficial ownership stake in Replimune Group, Inc. as of March 31, 2025.
NASDAQ
SCHEDULE 13G/A: Forbion Entities Maintain Significant Stake in Replimune Group, Disclosing 6.1% Beneficial Ownership
Forbion Capital Fund III Cooperatief U.A. and Forbion III Management B.V. have filed an amended Schedule 13G, reporting a continued beneficial ownership of 6.1% in Replimune Group, Inc.'s common stock as of December 31, 2024.
NASDAQ
The Vanguard Group has filed an amended Schedule 13G, reporting a 4.77% beneficial ownership stake in Replimune Group Inc. as of December 31, 2024.